Axium Healthcare Puerto Rico is proud to announce it is now dispensing:
VOXZOGO (vosoritide), for injection use treatment and is indicated:
PALYNZIQ (pegvaliese-pqpz), for injection use treatment and is indicated:
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Puerto Rico Specialty Pharmacy, recently shared what access to VOXZOGO and PALYNZIQ means for the rare disease community. “The Rare Disease community in the past few years is benefiting from the latest science developments providing hope due to the lack of treatment options. We are very proud to add both VOXZOGO AND PALYNZIQ to our treatment options for patients with Enzyme Deficiencies.”
At Axium Healthcare Puerto Rico our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Rare Diseases. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare Pharmacy Puerto Rico:
At Axium Healthcare Puerto Rico, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare Puerto Rico offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare Puerto Rico services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening genetic diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company's portfolio consists of eight commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. For additional information, please visit www.biomarin.com. www.biomarin.com.
VOXZOGO® and PALYNZIQ® are registered trademarks of BioMarin. Any other trademarks referred to in this release are the property of their respective owners.